Hypertension Management in Patients with Proteinuria and Cardiovascular Risk

Blood‑Pressure Targets and Goals

The European Society of Cardiology (ESC) guideline recommends a blood‑pressure target < 130/80 mmHg, ideally a systolic pressure of 120‑129 mmHg, for patients with hypertension and proteinuria to reduce cardiovascular and renal risk. 1
Achieving the target < 130/80 mmHg should be confirmed with office, home, or 24‑hour ambulatory measurements; home BP ≥ 135/85 mmHg or ambulatory BP ≥ 130/80 mmHg indicates uncontrolled hypertension. [4][1]

Spot urine albumin‑to‑creatinine ratio (ACR) should be obtained; an ACR ≥ 30 mg/mmol (≥ 265 mg/g) confirms clinically significant proteinuria. [4][1]
The presence of hypertension together with proteinuria defines hypertension‑mediated kidney damage, warranting intensified antihypertensive therapy. 1
Serum creatinine and eGFR (CKD‑EPI equation) must be measured to stage chronic kidney disease; an eGFR < 60 mL/min/1.73 m² or confirmed proteinuria establishes CKD and triggers at‑least‑annual monitoring. [1][2]

In patients with proteinuria, amlodipine monotherapy is insufficient; adding an ACE inhibitor (e.g., lisinopril) or an ARB (e.g., losartan) as a second agent provides blood‑pressure‑independent antiproteinuric effects and slows renal disease progression. 1

Serum potassium and creatinine should be re‑checked 2‑4 weeks after starting an ACE‑I or ARB to detect hyperkalaemia or acute kidney injury. 1

If BP remains ≥ 140/90 mmHg after 2‑4 weeks of dual therapy, a thiazide‑like diuretic (chlorthalidone preferred) should be added to achieve guideline‑recommended triple therapy (ACE‑I/ARB + CCB + thiazide). 1

Any subtle systolic murmur in a hypertensive patient warrants transthoracic echocardiography to evaluate for left‑ventricular hypertrophy, valvular disease, or other structural abnormalities; LVH on echo predicts cardiovascular mortality. 1
A 12‑lead ECG should be performed to screen for LVH, arrhythmias, or ischemic changes in all hypertensive patients. [3][1]

Basic secondary‑hypertension screening includes a detailed history, physical examination, serum sodium, potassium, eGFR, thyroid‑stimulating hormone, and urinalysis. [4][8]

Sodium intake < 2 g/day (≈ 5 g salt) can lower systolic BP by 5‑10 mmHg and enhances the efficacy of ACE‑I/ARB and diuretics. 1
Limiting alcohol to ≤ 1 standard drink per day for women (≤ 100 g/week) contributes to BP reduction. 1

Short‑term (2‑4 weeks): repeat office/home BP, serum potassium and creatinine, spot urine ACR, ECG, and echocardiography. 1
Medium‑term (4‑12 weeks): reassess BP control; if ≥ 140/90 mmHg, add thiazide‑like diuretic and re‑check electrolytes 2‑4 weeks later. 1
Long‑term (≥ 3 months): aim to achieve BP < 130/80 mmHg and maintain LDL‑C < 1.8 mmol/L; continue annual eGFR and ACR monitoring for CKD progression. 1

Do not delay intensification of antihypertensive therapy when proteinuria is present, as early control slows renal disease and reduces cardiovascular events. 1
Avoid dual renin‑angiotensin system blockade (combining ACE‑I with ARB) because it increases the risk of hyperkalaemia and acute kidney injury without added benefit. 1
Do not use a beta‑blocker as the second or third antihypertensive agent unless there is a compelling indication (e.g., angina, post‑MI, HFrEF, atrial fibrillation). 1
Confirm medication adherence and exclude white‑coat hypertension before labeling therapy as “failed.” 1
Proteinuria must be quantified and addressed aggressively; ignoring it leads to unchecked renal deterioration. 1